Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lineage Cell Therapeutics Inc (NY: LCTX ) 1.060 -0.010 (-0.93%) Official Closing Price Updated: 8:00 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 493,682 Open 1.070 Bid (Size) 1.040 (6) Ask (Size) 1.080 (6) Prev. Close 1.070 Today's Range 1.010 - 1.070 52wk Range 0.8372 - 1.560 Shares Outstanding 174,986,671 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index July 02, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage to Present at 2024 BIO International Convention May 30, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Performance YTD -2.75% -2.75% 1 Month +17.11% +17.11% 3 Month -17.83% -17.83% 6 Month -4.50% -4.50% 1 Year -27.40% -27.40% More News Read More Lineage Cell Therapeutics: Q4 Earnings Insights March 07, 2024 Via Benzinga A Preview Of Lineage Cell Therapeutics's Earnings March 06, 2024 Via Benzinga Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium May 21, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit May 06, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 May 02, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Changes to Board of Directors April 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) April 30, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 07, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development April 01, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 February 29, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium March 18, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session February 14, 2024 Via Benzinga RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit March 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting March 11, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering February 09, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Earnings Scheduled For March 7, 2024 March 07, 2024 Via Benzinga Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury February 13, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering February 06, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's After-Market Session February 01, 2024 Via Benzinga RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS January 16, 2024 From Lineage Cell Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
